Fluoxymesterone as Third Line Endocrine Therapy for Advanced Breast Cancer A Phase II Trial of the Piedmont Oncology Association

Schifeling, David J.; Jackson, Don V.; Zekan, Patricia J.; Muss, Hyman B.

doi:10.1097/00000421-199206000-00010

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High-dose megestrol acetate as third-line therapy for metastatic breast cancer did not result in mea surable response but may have been effective in delaying further progression for longer than 6 months in one third of the patients. Third-line endocrine therapy in patients with metastatic breast cancer has not been rigorously studied, but low response rates have been observed by Schifeling et al [8] and Tchckmedyian et al [6], Our results are in agreement with these data. In patients with metastatic breast cancer who show slowly progressive dis ease, the use of high-dose progestin therapy may be effec tive as a temporizing measure before the administration of chemotherapy.…”

Section: Discussionsupporting

confidence: 92%

High-Dose Megestrol Acetate as Third-Line Endocrine Therapy for Metastatic Breast Cancer

1992

Self Cite

View full text Add to dashboard Cite

High-dose megestrol acetate (800 mg/day) was administered to 34 patients as third-line endocrine therapy for metastatic breast cancer after progression on standard-dose megestrol acetate (160 mg/day). Among the 32 evaluable patients, no complete or partial response occurred. Ten patients remained stable and 22 progressed. No patients remained on study. Median time to progression was 2 months (range, 1-13 months). The use of high-dose megestrol acetate did not result in objective responses but may have been effective in delaying progression in one third of patients.

show abstract

Section: Discussionsupporting

confidence: 92%

High-Dose Megestrol Acetate as Third-Line Endocrine Therapy for Metastatic Breast Cancer

1992

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lastly, other available therapies for postmenopausal women with ER+ MBC include high‐dose estrogen and androgens . Androgenic agents such as nandrolone decanoate have been used as third‐line agents , and fluoxymesterone is an option for endocrine‐resistant disease . High‐dose ET (diethylstilbestrol or ethinylestradiol) may represent an option as a salvage treatment for postmenopausal women with late‐stage ER+ MBC after resistance to AI therapy .…”

Section: Resultsmentioning

confidence: 99%

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer

Kaklamani

Gradishar

2017

The Oncologist

View full text Add to dashboard Cite

Metastatic breast cancer (MBC) results in substantial morbidity and mortality for women afflicted with this disease. A majority of MBCs are hormone-responsive and estrogen receptor-positive, making endocrine therapy (ET) an integral component of systemic therapy. With a primary goal of minimizing the effects of estrogen on hormone-responsive MBC, ETs are among the first targeted treatments that aim to inhibit the influence of estrogen receptor activation on tumor proliferation. Several biochemical mechanisms have been the focus of drug development for treatment, including selective estrogen-receptor modulation, aromatase inhibition, and selective estrogen-receptor degradation. Treatments that exploit these mechanisms have improved survival and quality of life for women with MBC. However, in many cases, resistance to ET limits their effectiveness. Elucidation of the complex cellular signal cascades involved in the development of acquired resistance to ET and the interrelationship of growth factor signaling and estrogen responsiveness have characterized components of these pathways as attractive targets for drug development. Based on these insights and with the aim of overcoming hormone resistance, targeted therapies are emerging as useful treatments for MBC. This article reviews current endocrine treatments of MBC as well as recent and ongoing study of combination treatments and targeted therapies that interfere with cellular proliferation pathways as means of overcoming resistance. 2017;22:507-517 IMPLICATIONS FOR PRACTICE: This review provides medical oncologists and other oncology health care providers with a current understanding of the rationale for endocrine therapy in estrogen receptor-positive metastatic breast cancer and the efficacy and safety profile of available treatment options. Additionally, current concepts regarding the development of treatment resistance and the treatment strategies for overcoming resistance are discussed. Enhancing the current information and the understanding of these topics will assist clinicians in evaluating optimal treatment options for their patients.

show abstract

“…94,95 After the aforementioned options have been used, the following additional hormonal treatment options can be considered: megestrol acetate, fluoxymesterone, and high dose of estradiol. [96][97][98] Patients with HR-positive metastatic breast cancer can often be treated for years (or sometimes decades) with these therapeutic options while maintaining a good quality of life. If patients have been receiving various hormonal therapy agents for a long period of time, sometimes previously used drugs can be reused with beneficial results.…”

Section: Metastatic Breast Cancermentioning

confidence: 99%

Updates in the Evaluation and Management of Breast Cancer

O’Sullivan

Loprinzi

Haddad

2018

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed cancer worldwide. More than 200,000 new cases of invasive breast cancer are diagnosed annually in the United States; approximately 40,000 patients die of the disease. The etiology of most breast cancer cases is unknown, although multiple factors predisposing to the disease have been identified. Apart from increasing age and female sex, these other factors account for only a minority of breast cancer diagnoses. This article provides an overview of the management of noninvasive and invasive breast cancer, which is often complex and varies according to patient factors, disease stage, and breast cancer subtype. Although much progress has been made, continued research endeavors are ongoing; enrollment of eligible patients in prospective clinical trials is an essential way to improve patient outcomes.

show abstract

Fluoxymesterone as Third Line Endocrine Therapy for Advanced Breast Cancer A Phase II Trial of the Piedmont Oncology Association

Cited by 5 publications

References 0 publications

High-Dose Megestrol Acetate as Third-Line Endocrine Therapy for Metastatic Breast Cancer

High-Dose Megestrol Acetate as Third-Line Endocrine Therapy for Metastatic Breast Cancer

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer

Updates in the Evaluation and Management of Breast Cancer

Contact Info

Product

Resources

About